Flere klager på rot i forbindelse med tildeling av nye aksjer i BGBIO.

Selskapet selv vet ikke hvor mange aksjer som er utestående.

Total of shares 2,688,689,214. 🧐🧐🧐🧐🧐
Updated 26-04-2024
Major shareholders
History
Rank Shareholders Shares % of shares
1 METEVA AS 901,150,642 33.52
2 INVESTINOR DIREKTE AS 230,013,327 8.55
3 NORDNET BANK AB 153,186,304 5.70
4 BERA AS 83,768,426 3.12
5 NORDNET LIVSFORSIKRING AS 83,333,712 3.10
6 BOFAS INC PROPRIETARY ACCOUNT - NO 58,439,360 2.17
7 MP PENSJON PK 42,438,052 1.58
8 MARSTIA INVEST AS 40,255,805 1.50
9 MOHN MARIT 38,239,805 1.42
10 JAKOB HATTELAND HOLDING AS 37,700,000 1.40
11 SARSIA DEVELOPMENT AS 36,091,514 1.34
12 CARNEGIE INVESTMENT BANK AB 33,466,135 1.24
13 HØSE AS 31,006,588 1.15
14 DANSKE BANK A/S 24,102,932 0.90
15 CAGSON AG 24,000,000 0.89
16 ZAIM KEVIN 21,700,000 0.81
17 SKANDINAVISKA ENSKILDA BANKEN AB 18,394,996 0.68
18 AVANZA BANK AB MEGLERKONTO 15,785,629 0.59
19 J.P. MORGAN SE 15,347,938 0.57
20 JAHATT AS 15,075,000 0.56
20 largest shareholders total 1,903,496,165 70.80
Other shares 785,193,049 29.20
Total 2,688,689,214 100.00
Data provided by Oslo Market Solutions AS
Supplied by © Euroland.com
Disclaimer
Cookie policy

Det ble opplyst 25.04 at selskapet nå har flg antall aksjer

Bergen, Norway, 25 April 2024 - Reference is made to the stock exchange
announcement by BerGenBio ASA (the "Company") on 16 April 2024 regarding the
final results of the last exercise period for the warrants ("Warrants") issued
in connection with the rights issue, which resulted in an allocation of
1,106,565,434 new shares in the Company ("New Shares") to investors holding
Warrants. A reference is also made to the stock exchange announcement by
BerGenBio ASA on 17 April 2024 regarding an increase of the Company's share
capital by issuance of 113,456,919 new shares in connection with settlement of
underwriting commission in accordance with underwriting agreements dated 1 April
2024 and made by and between the Company and the underwriters (the "Fee
Shares").

The share capital increases pertaining to the New Shares and the Fee Shares are
now registered with the Norwegian Register of Business Enterprises. After this,
the Company's new registered share capital is NOK 390,871,156.70 divided into
3,908,711,567 shares, each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.